Stockscreener 앱 받기
1.075
2.38%
0.025
Tscan Therapeutics Inc 주식(TCRX)의 최신 뉴스
Enterprise value to EBITDA forward of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
Enterprise value to EBIT forward of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
TScan Therapeutics at H.C. Wainwright: phase iii push gains pace By Investing.com - Investing.com Canada
TScan Therapeutics at H.C. Wainwright: phase iii push gains pace - Investing.com
Enterprise value to revenue forward of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
Price to sales forward of TScan Therapeutics, Inc. – BOATS:TCRX - TradingView
Price to earnings forward of TScan Therapeutics, Inc. – BOATS:TCRX - TradingView
TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates - MSN
TScan Therapeutics, Inc. Actuals & Estimates (NASDAQ:TCRX) - TradingView
TCRX Forecast — Price Target — Prediction for 2027 - TradingView
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire
H.C. Wainwright reiterates Tscan stock rating on trial data - Investing.com UK
H.C. Wainwright reiterates Tscan stock rating on trial data By Investing.com - Investing.com South Africa
TCRX Reiterated by Wedbush -- Price Target Maintained at $5.00 - GuruFocus
TCRX Reiterated by Needham -- Price Target Maintained at $6.00 - GuruFocus
A Quick Look at Today's Ratings for TScan Therapeutics(TCRX.US), With a Forecast Between $5 to $7 - Moomoo
TScan Therapeutics Price Target Maintained With a $6.00/Share by Needham - Moomoo
H.C. Wainwright Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Needham Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation - Sahm
TScan reports Phase 1 data for TSC-101 blood cancer trial - grafa.com
Form 8K Tscan Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial - TipRanks
TScan reports trial data for blood cancer treatment TSC-101 - Investing.com
TScan reports trial data for blood cancer treatment TSC-101 By Investing.com - Investing.com Australia
TCRX: Cohort C results support advancing TSC-101 to Phase 3, showing high efficacy and safety - TradingView
TScan Therapeutics (TCRX) shows strong TSC-101 Phase 1 data, plans pivotal trial - Stock Titan
TScan Therapeutics Announces Positive Initial Data from - GlobeNewswire
Number of shareholders of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
TScan Therapeutics Inc (TCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TScan Therapeutics Inc (TCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TScan Therapeutics Inc (TCRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TScan Therapeutics Inc (TCRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
TScan Therapeutics Inc (TCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TScan Therapeutics Inc (TCRX) Institutional Confidence - TradingKey
TScan Therapeutics Inc (TCRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TScan Therapeutics Inc (TCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TScan Therapeutics Inc (TCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TScan Therapeutics (TCRX) Declines Sharply as Biotech Sector Headwinds IntensifySector Sentiment - newsline.com
Cellares and TScan to assess automated manufacturing of TSC-101 therapy - Yahoo Finance
Cellares, TScan Partner to Automate Manufacture of TCR-T Candidate - Contract Pharma
Cellares, TScan to evaluate automated manufacturing for TSC-101 By Investing.com - Investing.com Australia
Cellares, TScan to evaluate automated manufacturing for TSC-101 - Investing.com
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies - Business Wire
TCRX Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Advances Without RevenueFinancial Summary - newsline.com
TScan Therapeutics Cuts Net Loss to 28 Million Dollars - asatunews.co.id
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss - Insider Monkey
TScan Therapeutics hangs around $1.08; eyes on next week - Bez Kabli
TScan Therapeutics Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances Clinical PipelineEPS Growth Report - The Legal Advocate
TCRXTscan Therapeutics Inc Stock Price and Quote - Finviz
TScan Therapeutics (TCRX) Rallies 3.9% as Shares Test Key Resistance LevelsPercent Below MA - The Legal Advocate
TScan Therapeutics Q1 2026 Earnings: Narrowing Loss Despite EPS Miss, Stock Gains on Pipeline ProgressConsensus Forecast Report - The Legal Advocate
TScan Therapeutics Expands Authorized Shares After Stockholder Vote - The Globe and Mail
1.03%
2.69%
자본화:
|
볼륨(24시간):